https://www.clinicaltrialsarena.com/news/bridgebio-gears-up-for-fda-review-of-acoramidis-following-phase-iii-results/
BridgeBio submitted the NDA with US FDA for the TTR stabiliser in December 2023 and plans to engage with other regulatory bodies this year.
bridgebiogearsfdareviewacoramidis
https://pubmed.ncbi.nlm.nih.gov/41384357/
A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy
plain languagereviewattributecmstudy